575 results on '"de Vries, E. G. E"'
Search Results
2. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
3. Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial
4. One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
5. Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
6. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
7. The antibody–drug conjugate target landscape across a broad range of tumour types
8. Molecular imaging in metastatic breast cancer
9. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
10. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
11. ESMO-Magnitude of Clinical Benefit Scale version 1.1
12. ATR inhibition preferentially targets homologous recombination-deficient tumor cells
13. Microenvironment involved in FPR1 expression by human glioblastomas
14. Prioritising systemic cancer therapies applying ESMO's tools and other resources to assist in improving cancer care globally
15. The Impact of Haematopoietic Growth Factors on Supportive Care in Clinical Oncology: With Special Attention to Potential Tumour Cell Contamination in the Stem Cell Harvest
16. Molecular imaging in ovarian cancer
17. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
18. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
19. Clinical implications of multidrug resistance to chemotherapy
20. Clinical Application of Cryopreserved Stem Cells and Platelets in a Bone Marrow Transplant Program
21. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors
22. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
23. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination
24. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation
25. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer
26. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
27. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients
28. [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
29. [Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
30. Genetic factors influencing Pyrimidine-antagonist chemotherapy
31. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
32. Neuropsychological investigation into the carcinoid syndrome
33. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment
34. Visualization of multidrug resistance in vivo
35. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer
36. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
37. Molecular imaging in metastatic breast cancer
38. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue
39. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers
40. Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1
41. [Ga-68]Ga-NODAGA-Il2 for imaging activated T-cells
42. Lesion detection by [Zr-89]Zr-DFO-girentuximab and [F-18] FDG-PET in patients with newly diagnosed metastatic renal cell carcinoma
43. When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree
44. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer
45. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects
46. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer
47. Long-term cardiac follow-up in survivors of a malignant bone tumour
48. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
49. Abstracts of papers and posters
50. Abstracts of papers and posters Clinical Pharmacological Meeting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.